Biosimilar Implementation: How US Can Learn From EU
This article was originally published in PharmAsia News
Executive Summary
Differences in payer policies have limited the biosimilar opportunity in some EU nations, and a new report points to examples the US should replicate or avoid as biosimilars are introduced domestically, providing useful pointers to Asian firms active in the sector and looking to make filings in the US.